Patent ID: 7557109

Claim:
A method of treating attention-deficit/hyperactivity disorder (ADHD) in humans comprising administering to humans in need thereof a therapeutically effective amount of a compound according to the formula wherein R 1 is hydrogen, alkyl, cycloalkyl, optionally esterified hydroxyalkyl, alkoxyalkyl, optionally substituted phenyl or heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkoxycarbonyl, aminocarbonyl, alkyl- or dialkyl-aminocarbonyl, nitro, amino, alkyl- or dialkyl-amino, alkylsulfonylamino, arylamino, cyano, halogen, trifluoromethyl, trifluoromethoxy, optionally esterified hydroxyl, alkyl- or amino-sulphonyl or -sulphinyl, alkyl- or dialkyl-aminosulphonyl or -sulphinyl, and p has the value 0-3; R 2 and R′ 2 are independently hydrogen or an alkyl group and n and q can have the value 0 or 1; R 3 is hydrogen, and m has the value 0-2; A forms, with the two carbon atoms of the phenyl group, an optionally entirely or partly unsaturated cyclic group having 6 atoms in the ring, which comprises 2 or 3 hetero atoms selected from the group consisting of O, S, and N, with the proviso that the sum of the number of oxygen and sulphur atoms is at most 2; wherein the compound may be a racemate or a single diastereomer or enantiomer; or a pharmaceutically acceptable acid addition salt thereof.